Clinical trials: Myopic Choroidal Neovascularisation
- Condition Myopic Choroidal Neovascularisation
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Choroidal Neovascularization
Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
The objectives of this study are to investigate the safety and effectiveness of EYLEA.
- Trial name
- NCT02260687
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 353 people
- Sponsor
- Bayer